Education
About Us
Working with TipRanks
Follow Us
Engene Holdings Inc. (ENGN)
:ENGN
ENGN Stock Chart & Stats
$8.81
$0.17(2.19%)
At close: 4:00 PM EST
$8.81
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$2.65 - $11.00
Previous CloseN/A
Volume16.79K
Average Volume (3M)375.58K
Market Cap
$424.38M
Enterprise Value$23.05M
Total Cash (Recent Filing)$201.91M
Total Debt (Recent Filing)$8.26M
Price to Earnings (P/E)―
Beta-1.68
Next Earnings
Mar 16, 2026EPS EstimateN/A
Last Dividend Ex-Date
Feb 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding51,191,772
10 Day Avg. Volume417,203
30 Day Avg. Volume375,580
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-8.03
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue48.03
Enterprise Value/Gross Profit-235.23
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$23.33Price Target Upside164.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market AdoptionDetalimogene is positioned to capture sizable market share, particularly within the community practice setting.
Product AdvantagesDetalimogene's value lies in its ease of use, logistical simplicity, and seamless integration into existing outpatient workflows.
Regulatory ApprovalThe FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation allows heightened regulatory interaction and has historically compressed timelines, increasing detalimogene’s chances of capturing share.
Bears Say
Competitive LandscapeThe bar for CR durability is high, with cretostimogene showing superior remission rates and a clean safety profile.
enGene Holdings News
ENGN FAQ
What was Engene Holdings Inc.’s price range in the past 12 months?
Engene Holdings Inc. lowest stock price was $2.65 and its highest was $11.00 in the past 12 months.
What is Engene Holdings Inc.’s market cap?
Engene Holdings Inc.’s market cap is $424.38M.
When is Engene Holdings Inc.’s upcoming earnings report date?
Engene Holdings Inc.’s upcoming earnings report date is Mar 16, 2026 which is in 151 days.
How were Engene Holdings Inc.’s earnings last quarter?
Engene Holdings Inc. released its earnings results on Sep 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.498 by -$0.072.
Is Engene Holdings Inc. overvalued?
According to Wall Street analysts Engene Holdings Inc.’s price is currently Undervalued.
Does Engene Holdings Inc. pay dividends?
Engene Holdings Inc. pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on Engene Holdings Inc. dividends here
What is Engene Holdings Inc.’s EPS estimate?
Engene Holdings Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Engene Holdings Inc. have?
Engene Holdings Inc. has 51,191,772 shares outstanding.
What happened to Engene Holdings Inc.’s price movement after its last earnings report?
Engene Holdings Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.498. Following the earnings report the stock price went down -5.776%.
Which hedge fund is a major shareholder of Engene Holdings Inc.?
Currently, no hedge funds are holding shares in ENGN
enGene Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.33 (164.81% Upside)
$23.33 (164.81% Upside)
Blogger Sentiment
Bearish
ENGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 19.2%
Last 30 Days ▲ 19.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.11%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
-7.99%
Trailing 12-Months
Company Description
Engene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$23.33
▲(164.81% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
19.13% Insiders
0.27% Mutual Funds
66.89% Other Institutional Investors
13.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---